CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes
- 31 January 2014
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 21 (3) , 95-102
Abstract
CD40 ligand (CD40L) is a potent stimulator of tumor immunity via its activation of dendritic cells, which in turn initiate T-cell activation. However, T cells are inhibited by suppressive myeloid cells, which constitute an important part of immune evasion. We hypothesized that CD40L may revert the function of suppressive myeloid cells to generate a T-cell stimulatory environment, and this was investigated in the murine bladder cancer model MB49/C57BL/6. Upon intratumoral adenoviral CD40L (AdCD40L) gene therapy, the infiltration of CD11b+Gr-1+ cells was significantly reduced, whereas activated T cells were increased. In vitro, CD40L-expressing MB49 cells tilted the myeloid subpopulations in favor of granulocytic CD11b+Gr-1high myeloid cells instead of monocytic CD11b+Gr-1int/low myeloid cells. Further, the level of macrophages in splenocyte co-cultures with MB49 cells was evaluated. In cultures with MB49 cells expressing CD40L, the overall level of macrophages was reduced and the remaining cells were differentiated into M1-like cells. Hence, these data support that CD40L tilts myeloid immune cell populations in favor of anti-tumor immunity (M1) instead of immunosuppression (CD11b+Gr-1int/low and M2), and this was accompanied by an increased level of activated T cells in the tumor tissue.Keywords
This publication has 24 references indexed in Scilit:
- Tissue-based class control: the other side of toleranceNature Reviews Immunology, 2011
- AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa TrialClinical Cancer Research, 2010
- Subsets, expansion and activation of myeloid-derived suppressor cellsMedical Microbiology and Immunology, 2010
- Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG TherapyJournal of Immunotherapy, 2010
- Transforming growth factor beta (TGF-β) and inflammation in cancerCytokine & Growth Factor Reviews, 2010
- Immune Stimulatory Receptor CD40 Is Required for T-Cell Suppression and T Regulatory Cell Activation Mediated by Myeloid-Derived Suppressor Cells in CancerCancer Research, 2010
- Local AdCD40L Gene Therapy is Effective for Disseminated Murine Experimental Cancer by Breaking T-cell Tolerance and Inducing Tumor Cell Growth InhibitionJournal of Immunotherapy, 2009
- Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristicsJournal of Leukocyte Biology, 2008
- AdCD40LGene Therapy Counteracts T Regulatory Cells and Cures Aggressive Tumors in an Orthotopic Bladder Cancer ModelClinical Cancer Research, 2005
- Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.Journal of Experimental Medicine, 1996